Logo

Broadlane to Supply Cepheid's Molecular Dx Line to US Medical Facilities

Nov 29, 2007
NEW YORK (GenomeWeb News) – Healthcare supply company Broadlane will sell Cepheid’s molecular diagnostics instruments, reagents, and services to its customers, which include more than 20,000 healthcare facilities in the US, Cepheid said today. 
 
Broadlane’s client base includes acute care hospitals, ambulatory care facilities, and physician’s offices, Cepheid said.
 
The agreement covers Cepheid’s GeneXpert System and Xpert tests, which includes the company’s test kit for infections caused by methicillin-resistant Staphylococcus aureus.
 
Cepheid pointed out that a recently released study estimates that there were nearly 95,000 cases of MRSA in the US in 2005, resulting in around 18,650 deaths.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.